JV-1-39, Antagonist of GHRH receptor, CAS No.rp174395, Antagonist of GHRH receptor

CAS: rp174395 Cat. No.: rp174395

GRADE & PURITY Moligand™

Specifications

Product Name

JV-1-39, Antagonist of GHRH receptor, CAS No.rp174395

Grado

Moligand™

Specifiche e purezza

Moligand™

Tipo di azione

ANTAGONIST

Meccanismo d'azione

Antagonist of GHRH receptor

CAS

rp174395

Tipo di molecola

Peptidi

Product Line

Prodotti biologici

Stoccaggio e spedizione

Condizioni di conservazione di stoccaggio

Room temperature

Obiettivi associati (umani)

GHRHR Tclin Growth hormone-releasing hormone receptor (0 Activities)

Discover Target: GHRHR

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

Informazioni genetiche

• Reference:
  • 1. Kinetics and inhibition of recombinant human cystathionine gamma-lyase. Toward the rational control of transsulfuration., The Journal of biological chemistry, Steegborn, C C and 7 more authors.
  • 2. Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences., Proceedings of the National Academy of Sciences of the United States of America, Strausberg, Robert L RL and 83 more authors.
  • 3. Genomic basis of cystathioninuria (MIM 219500) revealed by multiple mutations in cystathionine gamma-lyase (CTH)., Human genetics, Wang, Jian J and Hegele, Robert A RA.
  • 4. Cloning and nucleotide sequence of human liver cDNA encoding for cystathionine gamma-lyase., Biochemical and biophysical research communications, Lu, Y Y, O'Dowd, B F BF, Orrego, H H and Israel, Y Y.
  • 5. Single nucleotide polymorphism in CTH associated with variation in plasma homocysteine concentration., Clinical genetics, Wang, J J, Huff, A M AM, Spence, J D JD and Hegele, R A RA.
  • 6. Cystathionine gamma-lyase overexpression inhibits cell proliferation via a H2S-dependent modulation of ERK1/2 phosphorylation and p21Cip/WAK-1., The Journal of biological chemistry, Yang, Guangdong G, Cao, Kun K, Wu, Lingyun L and Wang, Rui R.
  • 7. The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)., Genome research, Gerhard, Daniela S DS and 115 more authors.
  • 8. Towards a proteome-scale map of the human protein-protein interaction network., Nature, Rual, Jean-François JF and 37 more authors.
  • 9. The DNA sequence and biological annotation of human chromosome 1., Nature, Gregory, S G SG and 178 more authors.
  • 10. Polymorphisms in one-carbon metabolism and trans-sulfuration pathway genes and susceptibility to bladder cancer., International journal of cancer, Moore, Lee E LE and 14 more authors. more
  • 11. Toward a confocal subcellular atlas of the human proteome., Molecular & cellular proteomics : MCP, Barbe, Laurent L and 10 more authors.
  • 12. Kinetic properties of polymorphic variants and pathogenic mutants in human cystathionine gamma-lyase., Biochemistry, Zhu, Weidong W, Lin, Alexander A and Banerjee, Ruma R.
  • 13. Pathway-based evaluation of 380 candidate genes and lung cancer susceptibility suggests the importance of the cell cycle pathway., Carcinogenesis, Hosgood, H Dean HD and 12 more authors.
  • 14. Relationship between cystathionine gamma-lyase gene polymorphism and essential hypertension in Northern Chinese Han population., Chinese medical journal, Li, Yun Y and 8 more authors.
  • 15. Active cystathionine beta-synthase can be expressed in heme-free systems in the presence of metal-substituted porphyrins or a chemical chaperone., The Journal of biological chemistry, Majtan, Tomas T, Singh, Laishram R LR, Wang, Liqun L, Kruger, Warren D WD and Kraus, Jan P JP.
  • 16. MALDI-TOF MS genotyping of polymorphisms related to 1-carbon metabolism using common and mass-modified terminators., Clinical chemistry, Meyer, Klaus K, Fredriksen, Ase A and Ueland, Per Magne PM.
  • 17. Structural basis for the inhibition mechanism of human cystathionine gamma-lyase, an enzyme responsible for the production of H(2)S., The Journal of biological chemistry, Sun, Qingxiang Q and 10 more authors.
  • 18. Oral facial clefts and gene polymorphisms in metabolism of folate/one-carbon and vitamin A: a pathway-wide association study., Genetic epidemiology, Boyles, Abee L AL and 16 more authors.
  • 19. Large-scale proteomics and phosphoproteomics of urinary exosomes., Journal of the American Society of Nephrology : JASN, Gonzales, Patricia A PA and 7 more authors.
  • 20. An association study of 45 folate-related genes in spina bifida: Involvement of cubilin (CUBN) and tRNA aspartic acid methyltransferase 1 (TRDMT1)., Birth defects research. Part A, Clinical and molecular teratology, Franke, Barbara B and 7 more authors.
  • 21. Polymorphisms in innate immunity genes and lung cancer risk in Xuanwei, China., Environmental and molecular mutagenesis, Shen, Min M and 12 more authors.
  • 22. H2S biogenesis by human cystathionine gamma-lyase leads to the novel sulfur metabolites lanthionine and homolanthionine and is responsive to the grade of hyperhomocysteinemia., The Journal of biological chemistry, Chiku, Taurai T and 5 more authors.
  • 23. Variations in folate pathway genes are associated with unexplained female infertility., Fertility and sterility, Altmäe, Signe S and 7 more authors.
  • 24. Bile-acid-activated farnesoid X receptor regulates hydrogen sulfide production and hepatic microcirculation., World journal of gastroenterology, Renga, Barbara B, Mencarelli, Andrea A, Migliorati, Marco M, Distrutti, Eleonora E and Fiorucci, Stefano S.
  • 25. Cystathionine gamma-lyase: Clinical, metabolic, genetic, and structural studies., Molecular genetics and metabolism, Kraus, Jan P JP and 14 more authors.
  • 26. Relative contributions of cystathionine beta-synthase and gamma-cystathionase to H2S biogenesis via alternative trans-sulfuration reactions., The Journal of biological chemistry, Singh, Sangita S, Padovani, Dominique D, Leslie, Rachel A RA, Chiku, Taurai T and Banerjee, Ruma R.
  • 27. PTEN identified as important risk factor of chronic obstructive pulmonary disease., Respiratory medicine, Hosgood, H Dean HD, Menashe, Idan I, He, Xingzhou X, Chanock, Stephen S and Lan, Qing Q.
  • 28. Genetic susceptibility to distinct bladder cancer subphenotypes., European urology, Guey, Lin T LT and 18 more authors.
  • 29. Gene-centric association signals for lipids and apolipoproteins identified via the HumanCVD BeadChip., American journal of human genetics, Talmud, Philippa J PJ and 38 more authors.
  • 30. Integrative predictive model of coronary artery calcification in atherosclerosis., Circulation, McGeachie, Michael M and 13 more authors.
  • 31. Cystathionine beta-synthase 844Ins68 polymorphism is not associated with the levels of homocysteine and cysteine in an Indian population., Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals, Kumar, Jitender J, Garg, Gaurav G, Karthikeyan, Ganesan G and Sengupta, Shantanu S.
  • 32. The expression and activity of cystathionine-γ-lyase and 3-mercaptopyruvate sulfurtransferase in human neoplastic cell lines., Amino acids, Jurkowska, Halina H, Placha, Wojciech W, Nagahara, Noriuki N and Wróbel, Maria M.
  • 33. Ancient origin of the CTH alelle carrying the c.200C>T (p.T67I) variant in patients with cystathioninuria., Clinical genetics, Espinós, C C and 8 more authors.
  • 34. Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study., Diabetes care, Bailey, Swneke D SD and 11 more authors.
  • 35. Maternal genes and facial clefts in offspring: a comprehensive search for genetic associations in two population-based cleft studies from Scandinavia., PloS one, Jugessur, Astanand A and 12 more authors.
  • 36. [Expression of cystathionine-γ-lyase/hydrogen sulfide pathway in CVB3-induced myocarditis in mice]., Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics, Hua, Wang W and 6 more authors.
  • 37. Folate-metabolizing gene variants and pregnancy outcome of IVF., Reproductive biomedicine online, Laanpere, M M and 5 more authors.
  • 38. Specificity protein-1 as a critical regulator of human cystathionine gamma-lyase in smooth muscle cells., The Journal of biological chemistry, Yang, Guangdong G, Pei, Yanxi Y, Teng, Huajian H, Cao, Qiuhui Q and Wang, Rui R.
  • 39. Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium., Briefings in bioinformatics, Gaudet, Pascale P, Livstone, Michael S MS, Lewis, Suzanna E SE and Thomas, Paul D PD.
  • 40. Expression of cystathionine β-synthase and cystathionine γ-lyase in human pregnant myometrium and their roles in the control of uterine contractility., PloS one, You, Xing-Ji XJ and 8 more authors.
  • 41. MicroRNA-21 represses human cystathionine gamma-lyase expression by targeting at specificity protein-1 in smooth muscle cells., Journal of cellular physiology, Yang, Guangdong G, Pei, Yanxi Y, Cao, Qiuhui Q and Wang, Rui R.
  • 42. H2S-Induced sulfhydration of the phosphatase PTP1B and its role in the endoplasmic reticulum stress response., Science signaling, Krishnan, Navasona N, Fu, Cexiong C, Pappin, Darryl J DJ and Tonks, Nicholas K NK.
  • 43. Characterization of hydrogen sulfide and its synthases, cystathionine β-synthase and cystathionine γ-lyase, in human prostatic tissue and cells., Urology, Guo, Hui H and 5 more authors.
  • 44. Sp1 is involved in regulation of cystathionine γ-lyase gene expression and biological function by PI3K/Akt pathway in human hepatocellular carcinoma cell lines., Cellular signalling, Yin, Peng P and 12 more authors.
  • 45. H₂S protects against pressure overload-induced heart failure via upregulation of endothelial nitric oxide synthase., Circulation, Kondo, Kazuhisa K and 14 more authors.
  • 46. Reduced cystathionine γ-lyase and increased miR-21 expression are associated with increased vascular resistance in growth-restricted pregnancies: hydrogen sulfide as a placental vasodilator., The American journal of pathology, Cindrova-Davies, Tereza T and 5 more authors.
  • 47. Dysregulation of hydrogen sulfide producing enzyme cystathionine γ-lyase contributes to maternal hypertension and placental abnormalities in preeclampsia., Circulation, Wang, Keqing K and 14 more authors.
  • 48. Regulation of cystathionine γ-lyase in mammalian cells by hypoxia., Biochemical genetics, Wang, Maoxian M, Guo, Zhanyun Z and Wang, Shilong S.
  • 49. A genome-wide association study of chemotherapy-induced alopecia in breast cancer patients., Breast cancer research : BCR, Chung, Suyoun S and 6 more authors.
  • 50. [Cystathionine γ-lyase]., Postepy higieny i medycyny doswiadczalnej (Online), Jurkowska, Halina H, Kaczor-Kamińska, Marta M, Bronowicka-Adamska, Patrycja P and Wróbel, Maria M.
  • 51. Decreased cystathionine-γ-lyase (CSE) activity in livers of type 1 diabetic rats and peripheral blood mononuclear cells (PBMC) of type 1 diabetic patients., The Journal of biological chemistry, Manna, Prasenjit P, Gungor, Neslihan N, McVie, Robert R and Jain, Sushil K SK.
  • 52. Hydrogen sulfide (H2S)/cystathionine γ-lyase (CSE) pathway contributes to the proliferation of hepatoma cells., Mutation research, Pan, Yan Y and 5 more authors.
  • 53. The cystathionine γ-lyase/hydrogen sulfide system maintains cellular glutathione status., The Biochemical journal, Lee, Zheng-Wei ZW, Low, Yi-Lian YL, Huang, Shufen S, Wang, Tianxiao T and Deng, Lih-Wen LW.
  • 54. The binding site for the transcription factor, NF-κB, on the cystathionine γ-lyase promoter is critical for LPS-induced cystathionine γ-lyase expression., International journal of molecular medicine, Wang, Maoxian M, Guo, Zhanyun Z and Wang, Shilong S.
  • 55. Regulation of cystathionine gamma-lyase/H₂S system and its pathological implication., Frontiers in bioscience (Landmark edition), Zhao, Kexin K, Li, Hongzhu H, Li, Shuangshuang S and Yang, Guangdong G.
  • 56. Dysregulation of hydrogen sulphide metabolism impairs oviductal transport of embryos., Nature communications, Ning, Nannan N and 5 more authors.
  • 57. Wnt/β-catenin signaling induces the transcription of cystathionine-γ-lyase, a stimulator of tumor in colon cancer., Cellular signalling, Fan, Kun K and 7 more authors.
  • 58. miRNA-30 family inhibition protects against cardiac ischemic injury by regulating cystathionine-γ-lyase expression., Antioxidants & redox signaling, Shen, Yaqi Y and 7 more authors.
  • 59. Role of the cystathionine γ lyase/hydrogen sulfide pathway in human melanoma progression., Pigment cell & melanoma research, Panza, Elisabetta E and 11 more authors.
  • 60. A proteome-scale map of the human interactome network., Cell, Rolland, Thomas T and 69 more authors.
  • 61. Neurodegeneration in Huntington's disease involves loss of cystathionine γ-lyase., Cell cycle (Georgetown, Tex.), Paul, Bindu D BD and Snyder, Solomon H SH.
  • 62. The importance of MTHFR, MTR, MTRR and CSE expression levels in Caucasian women with preeclampsia., European journal of obstetrics, gynecology, and reproductive biology, Seremak-Mrozikiewicz, Agnieszka A and 6 more authors.
  • 63. The importance of rs1021737 and rs482843 polymorphisms of cystathionine gamma-lyase in the etiology of preeclampsia in the Caucasian population., Ginekologia polska, Mrozikiewicz, Przemysław M PM and 8 more authors.
  • 64. Cystathionine γ-lyase, a H2S-generating enzyme, is a GPBAR1-regulated gene and contributes to vasodilation caused by secondary bile acids., American journal of physiology. Heart and circulatory physiology, Renga, Barbara B and 9 more authors.
  • 65. Correlation between the cystathionine-γ-lyase (CES) and the severity of peptic ulcer disease., African health sciences, Chen, Xiong X, Wan, Ying-Chun YC, Guo, Tao T, Xu, Can-Xia CX and Wang, Fen F.
  • 66. MPST but not CSE is the primary regulator of hydrogen sulfide production and function in the coronary artery., American journal of physiology. Heart and circulatory physiology, Kuo, Maggie M MM and 10 more authors.
  • 67. Transcriptional Regulation of Cystathionine-γ-Lyase in Endothelial Cells by NADPH Oxidase 4-Dependent Signaling., The Journal of biological chemistry, Mistry, Rajesh K RK and 8 more authors.
  • 68. LPS Up-Regulates Cystathionine γ -Lyase Gene Expression in Primary Human Macrophages via NF-κB/ERK Pathway., Inflammation & allergy drug targets, Badiei, Alireza A, Gieseg, Steven S, Davies, Sian S, Izani Othman, Mohd M and Bhatia, Madhav M.
  • 69. Radiation Exposure Promotes Hepatocarcinoma Cell Invasion through Epithelial Mesenchymal Transition Mediated by H2S/CSE Pathway., Radiation research, Pan, Yan Y, Zhou, Cuiping C, Yuan, Dexiao D, Zhang, Jianghong J and Shao, Chunlin C.
  • 70. Cystathionine γ-lyase(CSE)/hydrogen sulfide system is regulated by miR-216a and influences cholesterol efflux in macrophages via the PI3K/AKT/ABCA1 pathway., Biochemical and biophysical research communications, Gong, Duo D and 15 more authors.
  • 71. MicroRNA-186 promotes macrophage lipid accumulation and secretion of pro-inflammatory cytokines by targeting cystathionine γ-lyase in THP-1 macrophages., Atherosclerosis, Yao, Yan Y and 9 more authors.
  • 72. Cystathionine γ-lyase is expressed in human atherosclerotic plaque microvessels and is involved in micro-angiogenesis., Scientific reports, van den Born, J C JC and 5 more authors.
  • 73. Dichotomous effects of isomeric secondary amines containing an aromatic nitrile and nitro group on human aortic smooth muscle cells via inhibition of cystathionine-γ-lyase., Biochimie, Ji, Yajing Y and 6 more authors.
  • 74. Distinctive expression pattern of cystathionine-β-synthase and cystathionine-γ-lyase identifies mesenchymal stromal cells transition to mineralizing osteoblasts., Journal of cellular physiology, Gambari, Laura L and 6 more authors.
  • 75. Age-Dependent Allergic Asthma Development and Cystathionine Gamma-Lyase Deficiency., Antioxidants & redox signaling, Wang, Peipei P and 6 more authors.
  • 76. Augmented H2S production via cystathionine-beta-synthase upregulation plays a role in pregnancy-associated uterine vasodilation., Biology of reproduction, Sheibani, Lili L and 7 more authors.
  • 77. Total sulfane sulfur bioavailability reflects ethnic and gender disparities in cardiovascular disease., Redox biology, Rajpal, Saurabh S and 12 more authors.
  • 78. Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides., Gene, Maruyama, K K and Sugano, S S.

Application Protocols

• Item-specific (Product Data)
  • No tested applications or recommended protocols are provided for this item.
• Guidance
  • In the absence of supplier protocols, follow your lab’s validated SOPs for compound handling and screening, and consult the CoA/SDS for any lot-specific notes (e.g., hygroscopicity, light sensitivity). Record solvent, concentration, and plate map to ensure reproducibility.

Biological Roles

• Item-specific (Product Data)
  • No biological function, pathway, or target information is provided for this item.
• Guidance (general; non-clinical)
  • For small-molecule library members, biological roles (e.g., enzyme modulation, receptor binding) must be confirmed from the supplier’s CoA/tech sheet or primary literature corresponding to the exact structure and salt form.
  • If biological characterization is required, perform orthogonal assays (biochemical potency, selectivity panel, and off-target counterscreens) under rigorously controlled vehicle concentrations and protein binding conditions.
• Compliance
  • For research use only, not for human or veterinary use, diagnostic, or therapeutic applications.

Buffer Applications

• Not typically applicable as a dedicated buffer component.
• General handling for assay dilution (general)
  • Prepare a concentrated DMSO stock, then dilute into an appropriate assay buffer (e.g., HEPES, Tris, or phosphate) ensuring the final organic solvent content is consistent across all wells/samples.
  • Include vehicle-only controls and consider surfactants (e.g., 0.01–0.05% Tween 20) if adsorption or aggregation is suspected.
  • For pH-sensitive readouts, confirm that any acid/base counterion in the supplied form does not appreciably shift buffer capacity at working concentrations.

Green Alternatives

• Context

  • Without structure-specific information, green assessment focuses on solvent handling and assay logistics rather than molecular hazards.

• Greener handling choices (general)

  • Prefer DMSO over chlorinated or highly hazardous aprotic solvents for stock solutions when compatible with your assays.
  • Use small-volume aliquots and seal microplates/vials to minimize waste and evaporative losses.
  • Employ aqueous buffers with minimal co-solvent where feasible; consider solubilization aids such as cyclodextrins to reduce organic content.

• Comparison of common stock-solution vehicles (general)

  | Vehicle | Greenness considerations | Notes | |---|---|---| | DMSO | Low volatility, relatively benign hazard profile; readily recyclable | Broad solvency; watch bioassay interference at >1% v/v | | Ethanol | Renewable feedstock, biodegradable | Volatile; flammability and plate-edge effects in HTS | | DMF | Reproductive toxin; less preferred | Use only if required for solubility; ensure closed systems | | ACN | Toxic, flammable; less preferred | Limit use to analytical workflows |

• Procurement/usage

  • Order only required quantities; consolidate shipments to reduce footprint.
  • Document solvent choice rationale in your green chemistry assessment.

Pharmaceutical Uses

• Not applicable for this catalog item.
• Notes
  • This product is supplied strictly for research use only. No formulation role, excipient status, or pharmacopeial monograph is provided.
  • Do not use for clinical, diagnostic, or therapeutic purposes. Any discussion of dosage forms or clinical applications is out of scope without explicit pharmacopeial or regulatory data.

Physical Properties

• Item-specific (Product Data)
  • Appearance: Not specified for this item; refer to CoA/Spec Sheet.
  • Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.
• Not specified for this item; refer to CoA/Spec Sheet for:
  • Melting point/boiling point
  • Density
  • Refractive index
  • UV/Vis characteristics or LC–MS retention data
  • Water content or residual solvents
  • Salt form/solvate state
• General guidance for small-molecule library compounds (literature/general)
  • Solubility is commonly established first in anhydrous DMSO (typical screening stocks 10–50 mM); aqueous solubility varies by chemotype and ionization state.
  • If ionizable, pKa strongly governs aqueous compatibility; consider preparing buffered working solutions after DMSO stock preparation.
  • For quality control, orthogonal ID methods such as LC–MS and 1H NMR are typically used; consult the CoA for the assay conditions used by the supplier.

Quality and Grades

• Item-specific (Product Data)
  • Grade: Moligand™.
  • Purity details, stabilizers, residual solvents, and analytical limits: Not specified for this item; refer to CoA/Spec Sheet.
• About Moligand™ (general description)
  • Moligand™ denotes a research-grade small-molecule/ligand library offering intended for discovery screening and assay development. Such offerings typically emphasize compound identity confirmation and suitability for in vitro research. Exact QC scope (e.g., NMR, LC–MS purity, salt form verification) should be confirmed in the item’s CoA.
• Practical considerations
  • Documentation: Use the provided CoA to capture lot-specific purity, analytical method(s), and any noted counterions/solvates.
  • Chromatography: If LC-based assays are planned, verify UV profile and LC–MS behavior from CoA to set detector wavelengths and gradients.
  • Stability: Long-term stability claims, if any, are CoA/SDS-dependent. In absence of detailed specs, prepare small aliquots and minimize freeze–thaw and light/air exposure.

Reaction and Applications

• Item-specific (Product Data)
  • Manufacturer application notes: Not specified for this item.
• Applicability to synthesis
  • This product is listed under a compound/library category and is not primarily positioned as a synthetic reagent or building block in the current listing. Without a disclosed structure, no reaction-class guidance can be provided for this specific item.
• Typical research uses for small-molecule library members (general, non-clinical)
  • In vitro screening and assay development as a reference compound or test article.
  • Mechanistic studies in biochemical or biophysical assays (e.g., binding, thermophoresis) after confirming identity and purity.
  • Analytical method development (e.g., retention-time markers) once UV/LC–MS properties are confirmed via CoA.
• Practical tips (general)
  • Prepare concentrated DMSO stocks, confirm clarity upon buffer dilution at working concentrations, and include matched vehicle controls.
  • Track compound history (solvent, concentration, number of freeze–thaw cycles, exposure to light/air) to ensure reproducibility.
  • Use orthogonal identity and purity checks (LC–MS, NMR) prior to critical studies.

Reaction Conditions

• Not applicable.
• Explanation
  • This catalog entry is categorized as a small-molecule library compound, not a reagent for use in chemical synthesis. Without a disclosed structure or intended transformation, typical reaction conditions cannot be responsibly recommended.

Safety and Handling

• Item-specific (Product Data)
  • GHS classification: Not specified for this item; refer to SDS.
  • Signal word / H-statements / pictograms: Not specified for this item; refer to SDS.
  • Storage condition: Room temperature (per Product Data).
• General laboratory precautions (general guidance)
  • Handle in a fume hood or well-ventilated area. Avoid inhalation of dust/aerosols and contact with skin/eyes. Use standard PPE: lab coat, safety glasses, and suitable gloves (e.g., nitrile).
  • Avoid incompatible materials until identity and functional groups are confirmed (strong oxidizers, strong acids/bases, reactive reducing agents).
  • If supplied as a dry film or powder, minimize static and airborne dispersion; open vials gently.
• First-aid overview (general guidance; defer to SDS)
  • Skin/eye contact: Rinse with water for several minutes; remove contaminated clothing. Seek medical attention if irritation persists.
  • Inhalation: Move to fresh air; monitor for respiratory irritation.
  • Ingestion: Rinse mouth. Do not induce vomiting. Seek medical advice.
• Waste
  • Collect in an appropriate organic waste stream. Follow institutional and local regulations.
• Always consult the official SDS for authoritative safety information before use.

Solvent Selection

• Item-specific (Product Data)
  • Specific solubility data are not provided; refer to CoA/Spec Sheet.
• General guidance for compound-library materials (literature/general)
  • Primary solvent: Anhydrous DMSO is the default for discovery stocks (e.g., 10–50 mM), owing to broad solvency and assay compatibility at low final percentages (≤0.5–1% v/v in wells).
  • Alternative solvents (if DMSO is unsuitable): DMF, ethanol, methanol, acetonitrile; for highly lipophilic compounds, co-solvent systems (DMSO + PEG400; DMSO + Tween 80; or aqueous buffer with ≤1% DMSO + cyclodextrin) can improve handling.
  • Aqueous use: After preparing a DMSO concentrate, dilute into assay buffer while vortexing to avoid precipitation; maintain consistent vehicle across controls.
  • pH effects: For ionizable compounds, adjust buffer pH to favor solubility of the predominant ionic form; consider using HEPES or phosphate buffers in the physiological pH range depending on assay.
• Comparison (general)
  • DMSO: highest solvency, widely accepted in screening; may affect some enzyme activities at >1%.
  • Ethanol: good for moderately polar compounds; higher volatility can complicate microplate uniformity.
  • ACN: strong solvency but can denature proteins; generally avoided in biochemical assays at >2–5%.

Storage and Reconstitution

• Item-specific (Product Data)
  • Storage conditions: Room temperature.
  • Shipped in: Not specified for this item; refer to CoA/Spec Sheet.
  • Appearance/form: Not specified for this item; refer to CoA/Spec Sheet.
• General guidance (non-specific; confirm with CoA before use)
  • Reconstitution: If supplied as a solid or thin film, prepare a concentrated stock in dry DMSO under inert atmosphere if feasible; verify complete dissolution and filter (0.22 µm PTFE) only if needed and compatible.
  • Aliquoting: Divide into single-use aliquots to avoid repeated freeze–thaw or prolonged bench exposure; clearly label concentration, solvent, and date.
  • Storage of solutions: Store DMSO stocks desiccated and protected from light. Many small-molecule stocks are kept at −20 °C to extend lifetime, but follow any item-specific notes on stability from the CoA.
  • Handling: Warm to ambient temperature before opening cold vials to prevent moisture condensation. Mix thoroughly after thawing and inspect for precipitates.
• Documentation
  • Retain CoA and SDS with the lot number, and record preparation details (solvent, lot, concentration) in your ELN for traceability.

Structure and Identity

• Item-specific (Product Data)
  • Product Name: JV-1-39 (SKU: rp174395)
  • CAS: rp174395 (catalog placeholder)
  • Grade: Moligand™
  • Molecular formula: Not specified for this item; refer to CoA/Spec Sheet.
  • Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.
  • SMILES: Not specified for this item; refer to CoA/Spec Sheet.
  • InChIKey: Not specified for this item; refer to CoA/Spec Sheet.
• Structural description
  • Specific structural features (functional groups, ring systems, stereocenters) are not provided in the current listing. Please consult the product’s CoA/Spec Sheet and SDS for the definitive structural identity, including any salt form, solvate state, or stereochemistry.
• General notes for compound-library items (general guidance)
  • Library members may be supplied as free base/acid, salt, or film in a microplate or vial. Verify exact identity and counterion by CoA before designing assays.
  • If you will register the compound in an ELN/ChemReg system, use the authoritative identifiers (SMILES, InChI, exact mass) from the CoA rather than secondary sources.

Synthetic Utility

• Not positioned as a synthetic building block in the current listing.
• Rationale
  • Due to the absence of structural information, no specific reactivity or named-reaction guidance can be provided for this item.
• General note
  • If the structure is later disclosed and you intend to repurpose it as a building block, consult functional-group compatibility, protecting-group strategies, and stability under common coupling/oxidation/reduction conditions based on that specific chemotype.

Target Specificity

• Item-specific (Product Data)
  • No target, selectivity panel, species reactivity, or binding data are provided for this item.
• Guidance (general)
  • If used as a test article in target-based assays, establish specificity via comparative profiling (e.g., enzyme family panels, receptor subtypes) and orthogonal modalities (biochemical vs. cellular) under matched vehicle conditions.

Domande frequenti

What are the CAS number, molecular formula and molecular weight?

The CAS Number is rp174395.